Last updated: 14 June 2019 at 3:30am EST

Stanley Lapidus Net Worth




The estimated Net Worth of Stanley Lapidus is at least $135 mil dollars as of 11 June 2019. Stanley Lapidus owns over 9,000 units of T2 Biosystems Inc stock worth over $121,923 and over the last 8 years Stanley sold TTOO stock worth over $12,960.

Stanley Lapidus TTOO stock SEC Form 4 insiders trading

Stanley has made over 3 trades of the T2 Biosystems Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Stanley sold 9,000 units of TTOO stock worth $12,960 on 11 June 2019.

The largest trade Stanley's ever made was exercising 27,058 units of T2 Biosystems Inc stock on 6 November 2018 worth over $31,387. On average, Stanley trades about 7,007 units every 92 days since 2016. As of 11 June 2019 Stanley still owns at least 53,010 units of T2 Biosystems Inc stock.

You can see the complete history of Stanley Lapidus stock trades at the bottom of the page.



What's Stanley Lapidus's mailing address?

Stanley's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.

Insiders trading at T2 Biosystems Inc

Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ... y Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.



What does T2 Biosystems Inc do?

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www



Complete history of Stanley Lapidus stock trades at T2 Biosystems Inc

Persona
Trans.
Transacción
Precio total
Stanley Lapidus
Director
Venta $12,960
11 Jun 2019
Stanley Lapidus
Director
Uso de opción $31,387
6 Nov 2018
Stanley Lapidus
Director
Uso de opción $23,200
6 Jun 2017


T2 Biosystems Inc executives and stock owners

T2 Biosystems Inc executives and other stock owners filed with the SEC include: